Europe Medicinal Chemistry for Drug Discovery Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-31
- Report ID: 143885
- Pages: 225
-
Format:
Short Description
Europe Medicinal Chemistry for Drug Discovery Market, By Process (Target Selection, Target Validation, Hit-To-Lead Identification, Lead Optimization and Candidate Validation), Design (Fragment-Based Variation, Structure-Based Drug Design, Diversity Oriented Synthesis, Chemogenomics, Natural Products and Others), Drug Type (Small Molecules and Biologics), Therapeutic Area (Oncology, Neurology, Infectious and Immune System Diseases, Cardiovascular Diseases, Digestive System Diseases and Others), End User (Contract Research Organization, Pharmaceuticals and Biotechnology Companies, Academic and Research Institutes and Others), Country (Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe) Industry Trends and Forecast to 2029
Market Definition:
Medicinal chemistry is the interdisciplinary field of science that involves a team of scientists (including synthetic organic chemists, analytical chemists, biologists, toxicologists, pharmacologists, microbiologists, and biopharmacists) working together for drug discovery, design, development and synthesis of new pharmaceuticals. Moreover, the contribution of medicinal chemistry is not confined just to the discovery stage. It carries its purpose along the entire spectrum of clinical development. Each and every stage of clinical development involves surplus amounts of formulated drugs for studying potential benefits in human trials. With time the chemical methods adopted for the discovery of the molecules have also undergone changes leading to the development of technologies such as combinatorial chemistry (combichem), microwave assisted organic synthesis (MAOS) and high-throughput (HTS) biological screening.
Market Segmentation:
Europe medicinal chemistry for drug discovery market is categorized into five notable segment which is process, design, drug type, therapeutic area and end user.
On the basis of process, the Europe medicinal chemistry for drug discovery market is segmented into target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. In 2022, target selection segment is expected to dominate the Europe medicinal chemistry for drug discovery market as it is the first process from where the drug discovery begins and where the biological targets are selected in an area of unmet medical needs.
On the basis of design, the Europe medicinal chemistry for drug discovery market is segmented into fragment-based variation, structure-based drug design, diversity oriented synthesis, chemogenomics, natural products and others. In 2022, the fragment based variation segment is expected to dominate the Europe medicinal chemistry for drug discovery market due to the fact that many potent compounds/ inhibitors of diverse targets have been developed using this method.
On the basis of drug type, the Europe medicinal chemistry for drug discovery market is segmented into small molecules and biologics. In 2022, small molecules segment is expected to dominate the market due to the fact that as per the market study most of the drug discovery organizations are highly focused on small molecules discovery and less focused on biologics including proteins, peptides among others.
On the basis of therapeutic area, the Europe medicinal chemistry for drug discovery market is segmented into oncology, infectious and immune system disease, neurology, cardiovascular disease, digestive system disease and others. In 2022, oncology segment is expected to dominate the market due to increasing prevalence of cancer and increasing number of clinical trials and research & development activities for development of novel therapeutics.
On the basis of end user, the Europe medicinal chemistry for drug discovery market is segmented into contract research organization, academic and research institutes, pharmaceutical & biotechnology companies and others. In 2022, contract research organization is expected to dominate in the Europe medicinal chemistry for drug discovery market because major market players signs collaborative agreement with contract research organizations for ongoing clinical trials in order to attain early drug development and approval.
Market Players
The key market players for Europe medicinal chemistry for drug discovery market are listed below:
Eurofins Scientific
Labcorp Drug Development
WuXi AppTec
Evotec SE
Pfizer Inc.
Sygnature Discovery
Thermo Fisher Scientific, Inc.
Charles River
Certara Inc
Domainex
Genscript Biotech
Aurigene Pharmaceutical Services
Malvern Panalytical Ltd (Parent Company Spectris PLC)
Aurelia Biosciences Ltd.
Taros Chemical GmBH & Co. KG
Selvita
TABLE OF CONTENTS
1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 OVERVIEW OF EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET 16
1.4 CURRENCY AND PRICING 18
1.5 LIMITATIONS 18
1.6 MARKETS COVERED 19
2 MARKET SEGMENTATION 21
2.1 MARKETS COVERED 21
2.2 GEOGRAPHICAL SCOPE 22
2.3 YEARS CONSIDERED FOR THE STUDY 23
2.4 DBMR TRIPOD DATA VALIDATION MODEL 24
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 27
2.6 MULTIVARIATE MODELLING 28
2.7 MARKET END USER COVERAGE GRID 29
2.8 PROCESS LIFELINE CURVE 30
2.9 DBMR MARKET POSITION GRID 31
2.10 VENDOR SHARE ANALYSIS 33
2.11 SECONDARY SOURCES 34
2.12 ASSUMPTIONS 34
3 EXECUTIVE SUMMARY 35
4 PREMIUM INSIGHTS 38
4.1 PESTEL ANALYSIS 39
4.2 POTERS FIVE FORCES 40
5 EUROPE MEDICINAL CHEMISTRY IN DRUG DISCOVERY MARKET: REGULATIONS 41
6 MARKET OVERVIEW 42
6.1 DRIVERS 44
6.1.1 INCREASE IN R&D FOR DISCOVERY AND DEVELOPMENT OF NOVEL DRUG MOLECULES 44
6.1.2 RISE IN CHRONIC DISEASES 44
6.1.3 INITIATIVES FOR RESEARCH ON RARE DISEASES AND ORPHAN DRUGS 45
6.1.4 GROWTH IN BIOLOGICS 45
6.1.5 COLLABORATIONS AMONG RESEARCHERS AND PHARMACEUTICAL INDUSTRIES 45
6.2 RESTRAINTS 46
6.2.1 RISE IN COST OF FORMULATED DRUG 46
6.2.2 TECHNICAL RISKS IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY 46
6.2.3 BIOETHICAL ISSUES IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY 47
6.3 OPPORTUNITIES 47
6.3.1 ADVANCEMENTS IN BIOCHEMICAL, TRANSLATIONAL, AND MOLECULAR STUDIES 47
6.3.2 RISE IN HEALTHCARE EXPENDITURE 47
6.3.3 USE OF ARTIFICIAL INTELLIGENCE IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY 48
6.4 CHALLENGES 48
6.4.1 BIOLOGICS NEED SPECIALIST TESTING SERVICES 48
6.4.2 STRINGENT REGULATIONS 49
7 IMPACT OF COVID-19 ON EUROPE MEDICINAL CHEMISTRY IN DRUG DISCOVERY MARKET 50
7.1 IMPACT ON PRICE 50
7.2 IMPACT ON DEMAND 50
7.3 IMPACT ON SUPPLY CHAIN 51
7.4 STRATEGIC DECISIONS BY MANUFACTURERS 51
7.5 CONCLUSION 52
8 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS 53
8.1 OVERVIEW 54
8.2 TARGET SELECTION 57
8.3 TARGET VALIDATION 57
8.4 HIT-TO-LEAD IDENTIFICATION 57
8.5 LEAD OPTIMIZATION 58
8.6 CANDIDATE VALIDATION 58
9 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN 59
9.1 OVERVIEW 60
9.2 FRAGMENT-BASED VARIATION 63
9.3 STRUCTURE BASED DRUG DESIGN 63
9.4 DIVERSITY ORIENTED SYNTHESIS 64
9.5 CHEMOGENOMICS 64
9.6 NATURAL PRODUCTS 64
9.7 OTHERS 65
10 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE 66
10.1 OVERVIEW 67
10.2 SMALL MOLECULES 70
10.3 BIOLOGICS 70
11 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA 71
11.1 OVERVIEW 72
11.2 ONCOLOGY 75
11.3 NEUROLOGY 75
11.4 INFECTIOUS AND IMMUNE SYSTEM DISEASES 76
11.5 CARDIOVASCULAR DISEASES 76
11.6 DIGESTIVE SYSTEM DISEASES 77
11.7 OTHERS 77
12 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER 78
12.1 OVERVIEW 79
12.2 CONTRACT RESEARCH ORGANIZATION 82
12.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 82
12.4 ACADEMIC AND RESEARCH INSTITUTES 83
12.5 OTHERS 83
13 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY COUNTRY 84
13.1 EUROPE 84
13.1.1 GERMANY 92
13.1.2 FRANCE 94
13.1.3 U.K. 96
13.1.4 ITALY 98
13.1.5 SPAIN 100
13.1.6 NETHERLANDS 102
13.1.7 RUSSIA 104
13.1.8 SWITZERLAND 106
13.1.9 BELGIUM 108
13.1.10 TURKEY 110
13.1.11 AUSTRIA 112
13.1.12 NORWAY 114
13.1.13 HUNGARY 116
13.1.14 LITHUANIA 118
13.1.15 IRELAND 120
13.1.16 POLAND 122
13.1.17 REST OF EUROPE 124
14 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: COMPANY LANDSCAPE 125
14.1 COMPANY SHARE ANALYSIS: EUROPE 125
15 SWOT ANALYSIS 126
16 COMPANY PROFILE 127
16.1 EUROFINS SCIENTIFIC 127
16.1.1 COMPANY SNAPSHOT 127
16.1.2 REVENUE ANALYSIS 128
16.1.3 COMPANY SHARE ANALYSIS 128
16.1.4 SERVICE PORTFOLIO 128
16.1.5 RECENT DEVELOPMENT 129
16.2 LABCORP DRUG DEVELOPMENT 130
16.2.1 COMPANY SNAPSHOT 130
16.2.2 REVENUE ANALYSIS 131
16.2.3 COMPANY SHARE ANALYSIS 131
16.2.4 SERVICE PORTFOLIO 132
16.2.5 RECENT DEVELOPMENT 132
16.3 CHARLES RIVER 133
16.3.1 COMPANY SNAPSHOT 133
16.3.2 REVENUE ANALYSIS 133
16.3.3 COMPANY SHARE ANALYSIS 134
16.3.4 SERVICE PORTFOLIO 134
16.3.5 RECENT DEVELOPMENTS 134
16.4 WUXI APPTEC 135
16.4.1 COMPANY SNAPSHOT 135
16.4.2 REVENUE ANALYSIS 135
16.4.3 COMPANY SHARE ANALYSIS 136
16.4.4 SERVICE PORTFOLIO 136
16.4.5 RECENT DEVELOPMENTS 136
16.5 EVOTEC SE 137
16.5.1 COMPANY SNAPSHOT 137
16.5.2 REVENUE ANALYSIS 137
16.5.3 COMPANY SHARE ANALYSIS 138
16.5.4 SERVICE PORTFOLIO 138
16.5.5 RECENT DEVELOPMENTS 138
16.6 PIRAMAL PHARMA SOLUTIONS 139
16.6.1 COMPANY SNAPSHOT 139
16.6.2 SERVICE PORTFOLIO 139
16.6.3 RECENT DEVELOPMENTS 139
16.7 THERMO FISHER SCIENTIFIC INC. 140
16.7.1 COMPANY SNAPSHOT 140
16.7.2 REVENUE ANALYSIS 140
16.7.3 SERVICE PORTFOLIO 141
16.7.4 RECENT DEVELOPMENT 141
16.7.4.1 ACQUISITION 141
16.8 AURIGENE PHARMACEUTICAL SERVICES (A SUBSIDIARY OF DR. REDDY'S LABORATORIES) 142
16.8.1 COMPANY SNAPSHOT 142
16.8.2 REVENUE ANALYSIS 142
16.8.3 SERVICE PORTFOLIO 143
16.8.4 RECENT DEVELOPMENT 143
16.9 AURELIA BIOSCIENCES 144
16.9.1 COMPANY SNAPSHOT 144
16.9.2 SERVICE PORTFOLIO 144
16.9.3 RECENT DEVELOPMENTS 144
16.10 BIOBLOCKS INC 145
16.10.1 COMPANY SNAPSHOT 145
16.10.2 SERVICE PORTFOLIO 145
16.10.3 RECENT DEVELOPMENT 145
16.11 CERTARA INC 146
16.11.1 COMPANY SNAPSHOT 146
16.11.2 REVENUE ANALYSIS 146
16.11.3 SERVICE PORTFOLIO 147
16.11.4 RECENT DEVELOPMENTS 147
16.12 DOMAINEX 148
16.12.1 COMPANY SNAPSHOT 148
16.12.2 SERVICE PORTFOLIO 148
16.12.3 RECENT DEVELOPMENT 148
16.13 GENSCRIPT BIOTECH 149
16.13.1 COMPANY SNAPSHOT 149
16.13.2 REVENUE ANALYSIS 149
16.13.3 SERVICE PORTFOLIO 150
16.13.4 RECENT DEVELOPMENT 150
16.14 PFIZER INC. 151
16.14.1 COMPANY SNAPSHOT 151
16.14.2 REVENUE ANALYSIS 151
16.14.3 SERVICE PORTFOLIO 152
16.14.4 RECENT DEVELOPMENTS 152
16.15 SELVITA 153
16.15.1 COMPANY SNAPSHOT 153
16.15.2 REVENUE ANALYSIS 153
16.15.3 SERVICE PORTFOLIO 154
16.15.4 RECENT DEVELOPMENTS 154
16.15.4.1 ACQUISITION 154
16.16 SPECTRIS PLC 155
16.16.1 COMPANY SNAPSHOT 155
16.16.2 REVENUE ANALYSIS 155
16.16.3 SERVICE PORTFOLIO 156
16.16.4 RECENT DEVELOPMENT 156
16.17 SYGNATURE DISCOVERY 157
16.17.1 COMPANY SNAPSHOT 157
16.17.2 SERVICE PORTFOLIO 157
16.17.3 RECENT DEVELOPMENTS 157
16.18 TAROS CHEMICAL GMBH 158
16.18.1 COMPANY SNAPSHOT 158
16.18.2 SERVICE PORTFOLIO 158
16.18.3 RECENT DEVELOPMENT 158
17 QUESTIONNAIRE 159
18 RELATED REPORTS 162
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
